Stryker (NYSE:SYK) Issues FY 2026 Earnings Guidance

Stryker (NYSE:SYK) updated its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 14.950-15.100 for the period, compared to the consensus earnings per share estimate of 14.980. The company issued revenue guidance of -.

Stryker Stock Down 6.2%

NYSE:SYK traded down $21.63 during midday trading on Friday, hitting $326.41. 4,522,496 shares of the company were exchanged, compared to its average volume of 2,374,153. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. Stryker has a fifty-two week low of $281.00 and a fifty-two week high of $401.99. The company has a market capitalization of $125.13 billion, a PE ratio of 37.78, a price-to-earnings-growth ratio of 2.26 and a beta of 0.77. The company has a fifty day simple moving average of $317.08 and a 200 day simple moving average of $334.98.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. During the same quarter last year, the company posted $3.13 earnings per share. The business’s quarterly revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities analysts anticipate that Stryker will post 14.99 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s payout ratio is 40.74%.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on SYK. BMO Capital Markets started coverage on shares of Stryker in a research report on Wednesday, July 8th. They set an “outperform” rating and a $369.00 target price on the stock. UBS Group began coverage on Stryker in a report on Tuesday. They issued a “buy” rating and a $400.00 price target for the company. Raymond James Financial set a $370.00 target price on shares of Stryker in a research report on Friday. BTIG Research cut their price target on shares of Stryker from $371.00 to $358.00 and set a “buy” rating for the company in a report on Friday. Finally, Argus set a $370.00 target price on shares of Stryker in a research report on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $387.88.

Insider Buying and Selling at Stryker

In other Stryker news, VP M Kathryn Fink sold 5,220 shares of the business’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the transaction, the vice president directly owned 13,137 shares in the company, valued at approximately $3,728,937.45. The trade was a 28.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the sale, the vice president owned 10,582 shares in the company, valued at $3,247,298.34. This trade represents a 30.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 323,264 shares of company stock worth $100,659,489. Corporate insiders own 4.60% of the company’s stock.

Trending Headlines about Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker reported second-quarter revenue of approximately $6.6 billion, up 9.4% year over year, while adjusted EPS rose 17.9% to $3.69, exceeding analysts’ expectations. Strong demand for orthopedic implants and other medical devices supported the results. Stryker beats quarterly estimates on strong demand for medical devices
• Positive Sentiment: Management said the business regained momentum after the March cyberattack and resumed share repurchases. Analysts remain broadly constructive: JPMorgan maintained an “overweight” rating with a $350 price target, while BTIG kept a “buy” rating with a $358 target. Analyst price-target updates
• Neutral Sentiment: Stryker narrowed its 2026 outlook to 8.3%-9.3% organic sales growth and adjusted EPS of $14.95-$15.10, versus prior ranges of 8.0%-9.5% and $14.90-$15.10. The change signals improving visibility but does not represent a significant earnings upgrade relative to elevated investor expectations. Stryker posts Q2 beats, narrows guidance after cyberattack recovery
• Negative Sentiment: The primary pressure on SYK appears to be an expectations reset: despite beating quarterly estimates, investors wanted a clearer upward revision following the cyber-disruption recovery. The stock’s premium valuation increases sensitivity to any guidance that merely meets forecasts. SYK Falls Despite Q2 Earnings Beat on Strong Sales and Cyber Recovery
• Negative Sentiment: Recent insider-activity data showed open-market selling rather than purchases over the past six months, including substantial sales attributed to Ronda E. Stryker. While not necessarily tied to the quarter, the activity may add to investor caution. Why Stryker Stock Is Falling Today

Hedge Funds Weigh In On Stryker

Hedge funds have recently made changes to their positions in the stock. Wellington Management Group LLP increased its holdings in shares of Stryker by 22.6% during the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock worth $2,282,192,000 after buying an additional 1,198,665 shares during the last quarter. Corient Private Wealth LLC boosted its holdings in Stryker by 104.4% in the second quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after acquiring an additional 1,146,998 shares during the last quarter. Credit Agricole S A acquired a new position in Stryker in the third quarter valued at $194,045,000. Dimensional Fund Advisors LP grew its position in Stryker by 35.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,260,651 shares of the medical technology company’s stock valued at $443,113,000 after acquiring an additional 327,490 shares during the period. Finally, Renaissance Technologies LLC grew its position in Stryker by 293.6% during the fourth quarter. Renaissance Technologies LLC now owns 406,160 shares of the medical technology company’s stock valued at $142,753,000 after acquiring an additional 302,960 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.